Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis

Curr Opin Mol Ther. 2005 Oct;7(5):493-501.

Abstract

sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Clinical Trials, Phase I as Topic
  • Drug Evaluation, Preclinical
  • Humans
  • Mice
  • Neoplasms / blood supply
  • Neoplasms / therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vascular Endothelial Growth Factor Receptor-1 / metabolism
  • Vascular Endothelial Growth Factor Receptor-1 / therapeutic use*
  • Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • Vascular Endothelial Growth Factor Receptor-2 / therapeutic use*

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor Receptor-2